PARIS, Oct. 15 /PRNewswire-FirstCall/ — Cellectis (Alternext:
ALCLS), the French genome engineering specialist, today published
its consolidated financial statement for the half-year ending June
30, 2010: revenues increased 25% over H1 2009, expenditure
increased 50% and the company ended the period with euro 38 million
in cash reserves.
During the first half of 2010, Cellectis entered into a number
of important new agreements (with BASF Plant Science, Boehringer
Ingelheim), published data in a peer-reviewed journal on the
therapeutic potential of meganucleases in Duchenne muscular
dystrophy and launched Cellectis plant sciences. Cellectis was also
granted the INPI National Innovation Award for its intellectual
property strategy. In addition, Cellectis’ research and production
tools subsidiary, Cellectis bioresearch, entered into a development
and commercial manufacturing agreement with Lonza that establishes
a presence for Cellectis in the bioproduction market.
“The figures for this half year reflect our growth
strategy,” said Andre Choulika, CEO at Cellectis.
“Cellectis’ staff has doubled in a year and comprises 130 people
today, in all entities, compared to 65 in July 2009. This has
allowed us to strengthen our position, in all aspects of our
business, with highly competent and committed people.“
“The capital increase that was made in October 2009 allows us
to finance this rapid growth and support our ambitious external
growth strategy,” added Marc Le Bozec, CFO at Cellectis.
The slide show presenting the half-year results in details is
available on http://www.cellectis.com/investors/accounts-and-reports
Simplified Income Statement – Financial items are presented
according to IFRSFigures in thousands of euros
first 6 months2009
first 6 monthsSales
6 2505 020Other revenue